Enveric Biosciences (ENVB) Stock: Buy, Sell, or Hold?
ENVB - Enveric Biosciences, Inc. Common Stock
$1.40
-0.07 (-4.76%)
▼
5d:
-4.76%
30d:
-5.41%
90d:
+6.06%
WAIT
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Nov 13, 2026
29d
Get Alerted When ENVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENVB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENVB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ENVB is currently trading at $1.40, which is considered oversold relative to its 30-day fair value range of $1.44 to $1.54.
Technical Outlook: Technically, ENVB is in a downtrend. The price is currently testing key support at $1.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+614.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENVB is in a downtrend. The price is currently testing key support at $1.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+614.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.44 -
$1.54
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 614.3% below Wall St target ($10.00)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.44 -
$1.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.38
Resistance Level
$1.53
Current Trend
Downtrend
Technical data as of
Oct 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$10.00
(+614.3%)
Revenue Growth (YoY)
-7.3%
Share & Embed Analysis
Last updated: October 14, 2026 7:32 AM ET
Data refreshes hourly during market hours. Next update: 8:32 AM
Data refreshes hourly during market hours. Next update: 8:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
24 analysts |
$84 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
ABVX
Abivax SA American Depos… |
STRONG BUY
12 analysts |
$164 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 44 HOLD |
